Moody Aldrich Partners LLC Protagonist Therapeutics, Inc Transaction History
Moody Aldrich Partners LLC
- $503 Million
- Q3 2024
A detailed history of Moody Aldrich Partners LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Moody Aldrich Partners LLC holds 119,287 shares of PTGX stock, worth $4.39 Million. This represents 1.07% of its overall portfolio holdings.
Number of Shares
119,287
Previous 134,215
11.12%
Holding current value
$4.39 Million
Previous $4.65 Million
15.27%
% of portfolio
1.07%
Previous 0.98%
Shares
6 transactions
Others Institutions Holding PTGX
# of Institutions
246Shares Held
56.7MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$216 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$212 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$200 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$155 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$117 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.81B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...